

ARTIGO CIENTÍFICO

# CONHECIMENTOS E PRÁTICAS DE ANESTESIOLOGISTAS SOBRE HIDRATAÇÃO PERIOPERATÓRIA EM PEDIATRIA

João Pedro Belo Osório Salzano Lago, Henrique Novaes Fonseca, Maria Eduarda Belo Osório Salzano Lago, Luciana Cavalcanti Lima

*Instituto de Medicina Integral Professor Fernando Figueira, Recife, PE, Brasil*

## **PALAVRAS-CHAVE:**

Hidratação  
perioperatória;  
Pediatria;  
Anestesiologia

## **Resumo**

*Introdução:* Existem diversas formas de hidratação perioperatória em pediatria, que se diferenciam pelos tipos de fluidos utilizados e modo de administração. Soluções isotônicas se mostraram superiores às hipotônicas, pois associam-se a menor morbimortalidade. Fórmulas para auxiliar a fluidoterapia em crianças foram criadas e aceitas pela comunidade de anestesistas pediátricos, sendo até hoje muito utilizadas. Não há diretrizes sobre a prescrição ideal de fluidos a ser adotada, o que torna essa prática muito variável, dependendo da experiência e preferência de cada profissional. O objetivo primário do estudo é avaliar o conhecimento e as práticas de condutas na hidratação perioperatória em pediatria adotadas pelos médicos e residentes de anestesiologia no Instituto de Medicina Integral Prof. Fernando Figueira – IMIP.

*Método:* Estudo descritivo de corte transversal. A metodologia escolhida foi a análise das respostas de um questionário dirigido aos médicos anesthesiologistas ativos e residentes de anestesiologia da instituição.

*Resultados:* Dos anesthesiologistas da instituição 37,7% responderam ao questionário, com uma média de idade de 38 anos, sendo 52,9% do sexo feminino e 44,1% do sexo masculino. 27 deles (79,4%) tiveram treinamento específico em relação a anestesia pediátrica. As soluções mais utilizadas foram Ringer Lactato e Solução Fisiológico 0,9% (SF0,9%). A maioria concordou com os eventos adversos propostos pelo estudo, com destaque para: 30 (90,9%) concordaram que relacionaram acidose hiperclorêmica com SF0,9%, 31 (91,2%) que relacionaram reação anafilática com coloide sintético e 31 (91,2%) que relacionaram hiponatremia com o uso de soluções glicoadas. 100% dos participantes utilizada a estratégia guiada por metas na administração de fluidos. 61,8% utiliza a fórmula de Holiday e Segar para cálculos de volume.

*Conclusão:* Identificou-se uma concordância entre os conhecimentos e práticas dos anesthesiologistas da instituição com o que propõe a literatura. Porém, sugere-se, ainda, o estabelecimento de uma diretriz sobre hidratação perioperatoria em pediatria.

## KEYWORDS

Hydration;  
Pediatrics;  
Anesthesiology

## Anesthesiologists' knowledge and practices about perioperative fluid therapy in pediatric patients

### Abstract

*Introduction:* There are several forms of perioperative hydration in pediatrics, which differ according to the types of fluids used and the mode of administration. Isotonic solutions proved to be superior to hypotonic ones, as they were associated with lower morbidity and mortality. Formulas to aid fluid therapy in children were created and accepted by the pediatric anesthetist community, and are still widely used today. There are no guidelines regarding the ideal fluid prescription to be adopted, which makes this practice very variable, depending on the experience and preference of each professional. The primary objective of the study is to evaluate the knowledge and practices of perioperative hydration practices in pediatrics adopted by anesthesiologists and residents of anesthesiology at Instituto de Medicina Integral Prof. Fernando Figueira – IMIP.

*Methods:* Descriptive cross-sectional study. The chosen methodology was the analysis of responses to a questionnaire addressed to active anesthesiologists and anesthesiology residents at the institution.

*Results:* 37,7% of the institution's anesthesiologists answered the questionnaire, with a mean age of 38 years, with 52.9% female and 44.1% male. 27 of them (79.4%) had specific training regarding pediatric anesthesia. The most used solutions were Lactate Ringer (LR) and 0.9%

Saline Solution. Most of them agreed with the adverse events proposed by the study, highlighting: 30 (90.9%) agreed that hyperchloremic acidosis is related to saline solution 0.9%, 31 (91.2%) that anaphylactic reaction is related to synthetic colloid and 31 (91.2%) who related hyponatremia with the use of glucose solutions. 100% of participants used the goal-directed therapy in fluid administration. 61.8% uses the Holiday and Segar formula for volume calculations.

*Conclusion:* A good concordance was identified between the knowledge and practices of the institution's anesthesiologists and that which studies the literature. However, it is still necessary to establish a guideline on perioperative hydration in pediatrics.

## Introdução

A administração de fluidos durante a anestesia é necessária para controlar o tônus vascular, manter o volume circulante e melhorar o débito cardíaco (DC). Tanto a administração excessiva de líquidos como a desidratação e a hipovolemia podem ser prejudiciais para os pacientes, e assim levar a consequências adversas.<sup>1</sup> Os efeitos adversos potenciais da fluidoterapia excessiva incluem sobrecarga de volume, edema pulmonar, edema tecidual, distúrbios eletrolíticos e ácido-básicos, exacerbação da hemorragia e coagulopatia por hemodiluição.<sup>2</sup> A taxa ideal de administração de fluidos durante a anestesia deve ser adaptada ao *status* volêmico do paciente, bem como à manutenção dos níveis normais de eletrólito sérico e do equilíbrio ácido-básico. O estado volêmico dos pacientes geralmente é avaliado indiretamente por meio de parâmetros que refletem a perfusão, mas as limitações desses métodos não garantem a manutenção adequada do volume em muitas situações. Pressão arterial, débito urinário e frequência cardíaca são parâmetros frequentemente utilizados para estimar a adequação do volume sanguíneo e da resposta à administração de líquidos.<sup>3,4</sup> O conhecimento do conteúdo de cada tipo de fluido é importante quando se planeja um regime apropriado de fluidos perioperatórios. A maioria dos pacientes que necessitam de terapia de manutenção intravenosa deve receber uma combinação de água, sódio, potássio e talvez glicose e outros eletrólitos, em um cristalóide iso-osmolar.<sup>5,6</sup> Em 1957, Holliday e Segar publicaram suas propostas para manejo de fluidos com base no gasto de energia e necessidades de fluidos de acordo com o peso corporal para crianças. A regra "4/2/1" recomenda que 4 mL/kg de solução balanceada, compreendendo uma concentração hipo-osmolar de sódio e glicose, deve ser administrada em crianças de 0 a 10 kg de peso corporal, 2

mL/kg para crianças de 11-20 kg somados a 40 mL e 1 mL/kg por cada kg em excesso 20 kg, somados a 60 mL.<sup>7,8</sup> Mais tarde, os próprios autores consideraram esse tipo de fluido inadequado para reposição perioperatória. O debate sobre a fluidoterapia intraoperatória ideal para pacientes pediátricos continua até os dias atuais. Há sim uma ampla variabilidade de prática, tanto entre indivíduos quanto instituições em termos do tipo de fluido, o momento de administração e o volume administrado. Esse debate deu origem a três estratégias de manejo de fluidos: a estratégia "liberal", a "restritiva" e a "objetiva".<sup>9</sup> Embora a administração de grande volume de líquidos, como é realizada na estratégia "liberal", possa expandir o conteúdo intravascular e melhorar a perfusão de órgãos, pode também aumentar a incidência de doença cardiopulmonar perioperatória e complicações na cicatrização de tecidos.<sup>10-12</sup> Por outro lado, restrição de líquidos, como propostana estratégia "restritiva", pode reduzir o tempo de internação, mas pode aumentar os riscos de lesão renal aguda (LRA) no pós-operatório.<sup>13</sup> Já a Terapia direcionada a objetivos (*GoalDirectedTherapy* - GDT), "objetiva", em que a administração individualizada de fluidos baseia-se em metas finais reproduzíveis foi associada a melhores resultados perioperatórios em pacientes de alto risco.<sup>14</sup>

Portanto, observa-se uma alta variabilidade nas práticas de prescrição de fluidos com poucas diretrizes para orientar uma adequada fluidoterapia em crianças durante procedimentos anestésico-cirúrgicos. No presente estudo, pretendeu-se avaliar o conhecimento e a prática dos anesthesiologistas sobre hidratação perioperatória em pediatria.

## Método

Foi realizado um estudo do tipo corte transversal no Instituto de Medicina Integral Prof. Fernando Figueira após a aprovação pelo Comitê de Ética em

Pesquisa em Seres Humanos da instituição (CAAE= 35750620.2.0000.5201) com anesthesiologistas e residentes de anesthesiologia, entre julho de 2020 e agosto de 2021, por meio de um questionário estruturado com questões envolvendo respostas simples e múltiplas desenvolvido a partir de diretrizes e artigos a respeito de conhecimentos e práticas sobre hidratação perioperatória em pediatria. Parte do questionário foi construído com base numa escala na qual os entrevistados especificam seu nível de concordância com uma afirmação. Para cada pergunta o entrevistado tinha as seguintes opções: discordo totalmente, discordo, não concordo e nem discordo e concordo. Foi realizada a pré-validação do instrumento (questionário) procedendo-se às seguintes etapas: A validação semântica ou FACE (com juizes não treinados - anesthesiologistas especialistas): foram selecionados 05 médicos anesthesiologistas com os mesmos critérios de inclusão no estudo, mas que não tomaram parte dele, para de forma presencial opinar sobre o instrumento quanto à: inteligibilidade, aspectos abordados, clareza dos itens, etc.; as sugestões de mudanças no instrumento sugeridas foram incorporadas quando houve consenso entre todos os membros do grupo. Esses especialistas avaliaram também a adequação do conteúdo do instrumento. As modificações sugeridas foram automaticamente incorporadas ao instrumento. Foram incluídos no estudo médicos anesthesiologistas e residentes de anesthesiologia que trabalham no IMIP. O único critério de exclusão foi ser anesthesista sem atuação em sala de cirurgia. Parte dos participantes foram convidados, em seu local de trabalho, a participar da pesquisa. Informava-se ao médico a finalidade da pesquisa e solicitava-se sua colaboração. Após sua aceitação e assinatura do termo de consentimento livre e esclarecido, entregava-se o questionário no início da manhã ou da tarde e era recolhido no fim do turno. Ele era orientado a não fazer pesquisa sobre o tema para responder as

perguntas contidas no questionário. O avaliador não ficava presente durante o preenchimento do questionário. Outra parte dos participantes foram contactados através de e-mail para o preenchimento do formulário via GoogleForms, após a aceitação do termo de consentimento, devido a pandemia e a limitação de acesso aos centros cirúrgicos do IMIP. A pesquisa foi realizada após assinatura do Termo de Consentimento Livre e Esclarecido (TCLE), de maneira que foram respeitados as normas e os princípios éticos contidos nas Resoluções 466/2012 e 510/2016 do Conselho Nacional de Saúde e no Código de Ética Médica que regem as pesquisas em seres humanos que tem fins acadêmicos.

## Resultados

Atuam no IMIP cerca de 60 anesthesiologistas e 27 residentes de anesthesiologia divididos em cinco centros cirúrgicos (geral, pediátrico, obstétrico, ambulatorial e transplante), além do centro de diagnóstico/ imagem e hemodinâmica. Do total, 34 entrevistados participaram da pesquisa, cinco contribuíram com a validação do questionário e 48 se recusaram ou não foram localizados. A média etária dos participantes foi igual a 38 anos (28 a 63). A mediana foi igual a 36 anos. Dos 34 entrevistados, 18 (52,9%) eram do sexo feminino e 15 (44,1%) do masculino e 1 (2,9%) não preencheu esse campo. Com relação a especialização em anesthesiologia, 30 (88,2%) eram médicos anesthesiologistas e 4 (11,8%) eram residentes de anesthesiologia. Deles, 27 (79,4%) responderam sim para treinamento específico em anesthesiologia pediátrica, 6 (17,6%) responderam não, e 1 (2,9%) não respondeu esse campo, Tabela 1. Quando perguntados sobre quais as soluções disponíveis para uso em anesthesiologia pediátrica, as soluções de maior destaque foram Ringer Lactato e Solução fisiológica 0,9%, com 100% e 97% de respostas positivas, respectivamente, como mostrado na tabela 2. Essas soluções também foram as mais

utilizadas pelos participantes na hidratação perioperatória em pediatria, com 33 (97,1%) concordando com o uso de Ringer Lactato e 28 (82,4%) concordando com o uso de Solução Fisiológica 0,9%. Dentre as soluções menos utilizadas, se destacaram Dextrans (20,6% discordaram totalmente e 38,2% discordaram) e Gelatina (20,6% discordaram totalmente e 38,2% discordaram), Tabela 3. Com relação aos eventos adversos relacionados ao Ringer Lactato, “edema periférico” foi o mais lembrado (76,5% concordaram). Por outro lado, o evento “hipercoagulabilidade” obteve os resultados de menor concordância (20,6%). Sobre os eventos adversos relacionados a soluções balanceadas, os entrevistados responderam de forma semelhante aos eventos adversos relacionados ao uso de Ringer Lactato, com edema periférico sendo o de maior concordância (70,6% concordaram), seguido de edema pulmonar (58,8% concordaram) e, por último, hipercoagulabilidade (38,2% de concordância). Já com relação aos eventos adversos relacionados ao uso de solução Fisiológica 0,9%, observou-se uma maior concordância com “acidose hiperclorêmica” (97,1% concordaram). Chamou atenção os 61,8% que concordaram com “retenção de fluidos”. Dos 34 participantes, 88,2% concordaram que as soluções balanceadas têm menor chance de causar acidose em relação a solução fisiológico 0,9%. E, 100% desses concordaram que grandes volumes de cristaloides podem causar acidose. Quando perguntados com relação aos eventos adversos dos coloides sintéticos, reação anafilática obteve resultados mais concordantes (91,2%), assim como coagulopatia (85,3%) e insuficiência renal (82,4%). Com relação aos eventos adversos relacionados a albumina, reação anafilática foi o evento com respostas mais concordantes (76,5%). Já com relação ao uso de soluções glicosadas, os eventos adversos questionados obtiveram alta concordância, com 91,2% concordando

com hiponatremia, 88,2% com hiperglicemia e 79,4% com dano cerebral. Tabelas 4 e 5. Quando questionados sobre as estratégias de fluidoterapia utilizadas na rotina (restritiva, liberal e guiada por metas), a guiada por metas obteve 100% de concordância. Com relação a estratégia restritiva, 94,1% dos participantes concordaram que lesão renal aguda é um de seus eventos adversos. Já na estratégia liberal, o evento adverso que mais chamou atenção foi “descompensação cardiopulmonar”, com 100% concordando. Sobre as fórmulas para cálculo de volume de reposição, 73,5% concordaram que conheciam a fórmula de Holliday e Segar (4/2/1), 58,8% concordaram que conheciam a fórmula de Furman e 41,2% concordaram que conheciam a fórmula de Berry. Dentre essas, a mais utilizada pelos participantes na prática clínica foi a fórmula de Holliday e Segar (61,8% concordaram). Dentre os 34 participantes da pesquisa, 100% concordaram sobre a necessidade de uma diretriz para fluidoterapia perioperatória em pediatria, Tabela 6.

## Discussão

Este estudo avaliou os conhecimentos e práticas dos anesthesiologistas de uma única instituição sobre hidratação perioperatória em pediatria. A hidratação perioperatória tem como objetivos manter as necessidades metabólicas basais, compensar déficits gerados pelo jejum pré-operatório e repor perdas relacionadas com o trauma cirúrgico, oferecendo o volume de fluidos necessário para manter a perfusão tecidual.<sup>15</sup> Assim, é imprescindível que todos os profissionais envolvidos na administração de fluidos estejam preparados para realizá-la com as soluções e volumes adequados, e que reconheçam os seus possíveis eventos adversos. A reposição de líquidos deve ser planejada com base na transferência de líquidos entre o compartimento extracelular e o espaço intersticial que resulta no volume chamado terceiro

espaço. Essa transferência pode ser diminuída se a reposição de volume intravascular for realizada com soluções de osmolaridade semelhantes à do líquido extracelular.

Neste estudo observou-se que as soluções de maior destaque na prática da anestesia perioperatória em pediatria foram Ringer Lactato (97,1%) e Solução Fisiológica 0,9% (82,4%), seguidas de Solução glicosilada 1%, solução fisiológica 0,9% + solução glicosilada 4%, solução glicosilada 2,4%, solução glicosilada 4%, albumina, gelatina, amido e dextrans. Quando comparamos com um estudo realizado na Inglaterra<sup>16</sup>, as mais utilizadas foram Solução Fisiológica 0,18%, Solução Glicosilada 4%, Ringer Lactato e Solução Fisiológica 0,9%, mostrando que, apesar da variabilidade, seguem o mesmo padrão.

Na prática clínica, a solução cristalóide mais utilizada é o Ringer Lactato. Quando comparado com o fluido extracelular, é ligeiramente hipotônico. O soro fisiológico tem osmolaridade praticamente igual à do fluido extracelular, porém, sua alta concentração de cloreto pode levar à acidose hiperclorêmica se utilizado em grandes volumes.<sup>17</sup> Em nosso estudo, observamos que os participantes concordam que os principais eventos adversos relacionados ao uso de Ringer Lactato foram edema periférico, edema pulmonar e hipercoagulabilidade, o que pode ser explicado pelo fato de ser uma solução ligeiramente hipotônica. Já com relação aos efeitos adversos relacionados ao Soro Fisiológico 0,9%, a maioria dos participantes deste estudo concordou que a acidose hiperclorêmica, retenção de fluidos e estados hiperosmolares são os mais frequentes. Além disso, 100% dos participantes concordaram que grandes volumes de cristalóides podem causar acidose, corroborando com essa afirmação, e 88,2% concordaram que o Ringer Lactato tem menor chance de causar acidose em relação a Solução Fisiológica 0,9%.

Já os colóides são soluções gelatinosas que contêm partículas muito

grandes para passarem pela membrana semipermeável, permanecendo no compartimento intravascular por mais tempo. Os colóides também aumentam o volume intravascular, aumentando, assim, a pressão oncótica intravascular. São divididos em dois grupos: colóides naturais e colóides sintéticos.<sup>18</sup> A albumina é um colóide natural altamente solúvel em água, que constitui 60% da proteína total no plasma. É improvável que a administração de albumina cause efeitos colaterais porque é um colóide de ocorrência natural.<sup>19</sup> As reações alérgicas podem ocorrer, embora aqueles vistos com a albumina sejam menos comuns do que com outros colóides. A interrupção da cascata de coagulação pode ocorrer devido aos efeitos na agregação plaquetária e ativação da antitrombina III.<sup>20</sup> Apesar desses raros efeitos colaterais, a albumina tem sido considerada o colóide padrão ouro para pacientes pediátricos. No presente estudo, 38,2% dos entrevistados são favoráveis ao uso de albumina. Com relação aos efeitos adversos, apesar de rara, a maioria reconhece a reação anafilática como evento adverso possível (76,5% de concordância), seguido de insuficiência renal (52,9% de concordância) e coagulopatia (44,1% de concordância).

No caso dos colóides sintéticos, os dextrans tem como principais vantagens um volume aumentado de expansão em comparação com a albumina e também a melhora da microcirculação.<sup>19</sup> Apesar do excelente efeito coloidosmótico, os dextrans têm alguns efeitos indesejáveis, como reações anafiláticas, hipocoagulabilidade e efeitos renais. Gelatinas, outra opção de colóide sintético, são polipeptídeos formados pela degradação do tecido conjuntivo animal, que têm um efeito oncótico inferior e mais curto quando comparado às soluções da mesma classe. Como outros colóides, há um efeito negativo na coagulação.<sup>19,21</sup> No presente estudo, a maioria dos participantes concordou que os principais efeitos adversos relacionados ao uso de colóides sintéticos

são reação anafilática (91,2%), coagulopatia (85,3%) e insuficiência renal (82,4%). Apenas os amidos de baixo peso molecular são liberados para uso em crianças no Brasil.

Desarranjos metabólicos relacionados ao jejum pré-operatório prolongado para crianças pequenas podem causar hipoglicemia, lipólise e cetoacidose. A glicose é a principal fonte de energia para o cérebro.<sup>22</sup> Sendo assim, as soluções glicosadas são bastante utilizadas na prática clínica, com o intuito de prevenir esses danos. As soluções de glicose não devem ser administradas como uma solução de substituição para perdas extraordinárias (sangramento, terceiro espaço, vômito, p.ex.) porque são soluções hipotônicas que produzem hiperglicemia e hiponatremia dilucional.<sup>23-26</sup> Em sua maioria, os participantes concordaram que o uso inadequado das soluções glicosadas pode acarretar efeitos indesejados, como os já citados anteriormente, hiperglicemia (88,2%), hiponatremia (91,2%) e, conseqüentemente, dano cerebral (79,4%).

Há uma ampla variabilidade de prática, tanto entre os indivíduos quanto instituições em termos do tipo de fluido usado, o momento de administração e o volume administrado. Na última década, esse debate deu origem a três estratégias de fluidoterapia: a "liberal", "restritiva" e "guiada por metas".<sup>27</sup> Embora a administração de grande volume de fluidos (estratégia liberal) possa expandir o espaço intravascular e melhorar a perfusão do órgão,<sup>28</sup> pode também aumentar a incidência de complicações cardiopulmonares e problemas de cicatrização de tecidos.<sup>29,30</sup> Por outro lado, a restrição de fluidos (estratégia restritiva) pode reduzir o tempo de internação; no entanto, pode aumentar o risco de lesão renal aguda (LRA) no pós-operatório.<sup>31</sup> A terapia guiada por metas (TGM), em que a administração de fluidos é individualizada com base em objetivos finais reproduzíveis, foi associada a melhores resultados perioperatórios.<sup>32</sup>

No estudo atual, quando questionados sobre as estratégias de fluidoterapia utilizadas, os entrevistados demonstraram 100% de concordância quanto a terapia guiada por metas, 38,2% quanto a estratégia restritiva e 17,6% quanto a liberal. Além disso, 94,1% concordaram que lesão renal aguda é um dos efeitos adversos da estratégia restritiva. Com relação aos efeitos adversos da estratégia liberal, 100% concordou com descompensação cardiopulmonar e 85,3% com complicações de cicatrização tecidual.

O volume e a composição da fluidoterapia perioperatória são baseados no *status* pré-operatório do paciente, no tipo de procedimento a ser realizado, e no tempo na sala de cirurgia e de recuperação estimado. A fórmula de Holliday e Segar's<sup>33</sup> permanece a mais comumente usada para calcular o volume de manutenção de fluidos perioperatórios em pediatria.<sup>23, 33, 34</sup> Os déficits de fluidos em jejum são calculados pelo número de horas para as quais os fluidos são restritos com a necessidade de fluido de manutenção. Em 1975, Furman et al. propôs substituir 50% de déficit hídrico em jejum na primeira hora e 25% na segunda e terceira horas. Essas diretrizes foram ainda simplificadas para pacientes com trauma por Berry et al.<sup>35</sup> Observamos que, 73,5% dos participantes concordaram que conheciam a fórmula de Holiday e Segar e 61,8% concordaram fazer o uso da mesma, 58,8% conheciam a fórmula de Furman e 41,2% a fórmula de Berry. Como limitações deste estudo, reconhecemos o número reduzido de participantes, 34, o que pode ser explicado devido as limitações impostas pela pandemia de COVID-19 ao longo do período de coleta de dados, que limitou acessos a blocos cirúrgicos, cirurgias eletivas e, nos obrigou a realizar questionários no meio virtual, resultando em baixa adesão por parte dos anestesistas. Porém, esse número representa mais de 30% dos anesthesiologistas da instituição, o que

acreditamos ser uma boa representatividade da população.

Dessa forma, conclui-se que a maioria dos anesthesiologistas participantes do estudo demonstrou conhecimentos e práticas sobre hidratação perioperatória em pediatria alinhados com o que a literatura propõe sobre o assunto. Entretanto, foi possível constatar algumas divergências, o que corrobora à necessidade de uma diretriz para fluidoterapia perioperatória em crianças.

## Referências

1. Kelm DJ, Perrin JT, Cartin R, et al. Fluid overload in patients with severe sepsis and septic shock treated with early goal directed therapy is associated with acute need for fluid-related medical intervention and hospital death. *Shock* 2015;43(1) 68–73.
2. Aldrich J. Shock fluid and fluid challenge. In: Silverstein D, Hopper K, editors. *Small animal critical care medicine*. 2nd edition. Philadelphia: Saunders Elsevier; 2015. p. 276–80
3. Mellema M. Cardiac output monitoring. In: Silverstein D, Hopper K, editors. *Small animal criticalcare medicine*. Philadelphia: Saunders Elsevier; 2009. p. 894–8.
4. Tantalean JA, Leon RJ, Santos AA, et al. Multiple organ dysfunction syndrome in children. *PediatrCritCareMed*2003;4:181–5.
5. Santos AA. Multiple organ dysfunction syndrome in children\*. *2003;4(2):181–5* 5.Powell-Tuck J, Gosling P, Lobo DN (2011) British consensus guidelines on intravenous fluid therapy for adult surgical patients.BAPEN Med.[www.bapen.org.uk/pdfs/bapen\\_publications/giftasup.pdf](http://www.bapen.org.uk/pdfs/bapen_publications/giftasup.pdf). Accessed 09 Sept 15
6. Padhi S, Bullock I, Li L, Stroud MR (2013) Intravenous fluid therapy for adults in hospital: summary of NICE guidance. *BritMed J* 347:f7073
7. Holliday MA, Segar WE. The maintenance need for water in parenteral fluid therapy. *Pediatrics* 1957; 19:823–832.
8. Edelson, Jonathan & Orenstein, Evan & Zaoutis, Lisa & Copelovitch, Lawrence. (2015). *Intravenous Fluid Management in the Pediatric Hospital Setting: Is Isotonic Fluid the Right Approach for all Patients?*. *Current Treatment Options in*



- Pediatrics. 1. 10.1007/s40746-014-0006 0.
9. Bundgaard-Nielsen M, Secher NH, Kehlet H. „Liberal“ vs. „restrictive“ perioperative fluid therapy – A critical assessment of the evidence. *Acta AnaesthesiolScand*2009;53:843-51.
  10. Prowle JR, Chua HR, Bagshaw SM, Bellomo R. Clinical review: Volume of fluid resuscitation and the incidence of acute kidney injury – A systematic review. *CritCare*2012;16:230.
  11. Brandstrup B, Tønnesen H, Beier-Holgersen R, Hjortsø E, Ørding H, Lindorff-Larsen K, *et al.* Effects of intravenous fluid restriction on postoperative complications: Comparison of two perioperative fluid regimens: A randomized assessor-blinded multicenter trial. *AnnSurg*2003;238:641-8.
  12. Holte K, Sharrock NE, Kehlet H. Pathophysiology and clinical implications of perioperative fluid excess. *Br J Anaesth*2002;89:622-32.
  13. Nisanevich V, Felsenstein I, Almogy G, Weissman C, Einav S, Matot I, *et al.* Effect of intraoperative fluid management on outcome after intraabdominal surgery. *Anesthesiology*2005;103:25-32.
  14. Kehlet H, Bundgaard-Nielsen M. Goal-directed perioperative fluid management: Why, when, and how? *Anesthesiology*2009;110:453-5.
  15. Murat I , Dubois MC . Perioperative fluid therapy in pediatrics. *PediatrAnesth* , 200 8 ;18: 363 -70.
  16. Way C, Dhamrait R, Wade A, Walker I. Perioperative fluid therapy in children: A survey of current prescribing practice. *Br J Anaesth.* 2006;97(3):371–9.)
  17. Kellum J, Mingchen S, Venkataraman R. Effects of hyperchloremic acidosis on arterial pressure and circulation inflammatory molecules in experimental sepsis. *Chest.* 2004; 125:243-8
  18. Sümpelmann R, Becke K, Brenner S, Breschan C, Eich C, Höhne C, *et al.* Perioperative intravenous fluid therapy in children: guidelines from the Association of the Scientific Medical Societies in Germany. *PaediatrAnaesth.*

- 2017;27(1):10–8
19. Mitra S, Khandelwal P. Are all colloids the same? How to select the right colloid? *Indian J Anesth.* 2009;53(5):592–607.
20. Baily AG, McNaull PP, Jooste E, Tuchman JB. Perioperative crystalloid and colloid fluid management in children: where are we and how did we get here? *PediatricAnesthesiol.* 2010;110(2):375–90.
21. Baily AG, McNaull PP, Jooste E, Tuchman JB. Perioperative crystalloid and colloid fluid management in children: where are we and how did we get here? *PediatricAnesthesiol.* 2010;110(2):375–90.
22. Kurz A. Perioperative Fluid Management
23. [http://www.apagbi.org.uk/sites/default/files/Perioperative\\_Fluid\\_Management\\_2007.pdf](http://www.apagbi.org.uk/sites/default/files/Perioperative_Fluid_Management_2007.pdf)
24. Montañana PA, Modesto i Alapont V, Ocon AP, Lopez PO, Lopez Prats JL, et al. (2008) The use of isotonic fluid as maintenance therapy prevents iatrogenic hyponatremia in pediatrics: A randomized, controlled openstudy. *PediatrCritCareMed* 9: 589-597.
25. Witt L, Osthaus WA, Lücke T, Jüttner B, Teich N, et al. (2010) Safety of glucose-containing solutions during accidental hyperinfusion in piglets. *Br J Anaesth* 105: 635-639.,
26. Leelanukrom R, Cunliffe M (2000) Intraoperative fluid and glucose management in children. *PaediatrAnaesth* 10: 353-359.
27. Bundgaard-Nielsen M, Secher NH, Kehlet H. ‘Liberal’ vs. ‘restrictive’ perioperative fluid therapy – A critical assessment of the evidence. *ActaAnaesthesiolScand*2009;53:843-51
28. Prowle JR, Chua HR, Bagshaw SM, Bellomo R. Clinical review: Volume of fluid resuscitation and the incidence of acute kidney injury – A systematic review. *CritCare*2012;16:230.
29. Brandstrup B, Tønnesen H, Beier-Holgersen R, Hjortsø E, Ørding H, Lindorff-Larsen K, et al. Effects of intravenous fluid restriction on postoperative complications: Comparison of two perioperative fluid regimens: A randomized

- assessor-blinded multicenter trial. *Ann Surg*2003;238:641-8.
30. Holte K, Sharrock NE, Kehlet H. Pathophysiology and clinical implications of perioperative fluid excess. *Br J Anaesth*2002;89:622-32.
31. Nisanevich V, Felsenstein I, Almogy G, Weissman C, Einav S, Matot I, et al. Effect of intraoperative fluid management on outcome after intraabdominal surgery. *Anesthesiology*2005;103:25-32.
32. Kehlet H, Bundgaard-Nielsen M. Goal-directed perioperative fluid management: Why, when, and how? *Anesthesiology*2009;110:453-5.
33. Holliday MA, Ray PE, Friedman AL (2007) Fluid therapy for children: Facts, fashions and questions. *ArchDisChild* 92: 546-550.
34. Mandee S, Butmangkun W, Aroonpruksakul N, Tantemsapya N, Von Bormann B, et al. (2015) Effects of a restrictive fluid regimen in pediatric patients undergoing major abdominal surgery. *PaediatrAnaesth* 25:530-537.
35. Berry F. Practical aspects of fluid and electrolyte therapy. In: Berry F, editor. *AnestheticManagement of Difficult and Routine Pediatric Patients*. New York: Churchill Livingstone;1986. p. 107–35.

**Tabela 1 –**

Variáveis	n	%	
<b>Sexo</b>			
Feminino	18	54,5	
Masculino	15	45,5	
<b>Atuação atual</b>			
Residente de anesthesiologia	4	11,8	
Médico anesthesiologista	30	88,2	
<b>Treinamento específico em relação a anestesia em pediatria</b>			
Sim	27	81,8	
Não	6	18,2	
<b>Na instituição em que você trabalha, há um protocolo para administração de fluidos no perioperatorio</b>			
Sim	5	14,7	
Não	29	85,3	
<b>Você acha necessária uma diretriz para fluidoterapiaperioperatoria em crianças</b>			
Sim	34	100,0	
Não	0	0,0	
	<b>Média ± DP</b>	<b>Mediana (Q1; Q3)</b>	<b>Mínimo – Máximo</b>
Idade (anos)	38,0 ± 8,4	36,0 (31,3; 40,8)	28,0 – 63,0

**Tabela 2 – Soluções disponíveis no serviço**

Variáveis	n	%
<b>Soluções disponíveis</b>		
Ringer lactato	34	100,0
Solução balanceada	8	23,5
Solução fisiológica 0.9%	33	97,1
Solução glicosada	31	91,2
Albumina	18	52,9
Gelatina	4	11,8
Amidos	7	20,6
Dextrans	5	14,7

**Tabela 3 – Soluções utilizadas na hidratação perioperatoria de pacientes pediátricos.**

Solução utilizada hidratação perioperatoria pacientes pediátricos	que na de	Discordo totalmente	Discordo	Não concordo nem discordo	Concordo
		n (%)	n (%)	n (%)	n (%)
Solução fisiológica		2 (5,9)	1 (2,9)	3 (8,8)	28 (82,4)

0,9%				
Soluções glicosadas	9 (26,5)	13 (38,2)	5 (14,7)	7 (20,6)
Solução glicosilada	5 (14,7)	7 (20,6)	10 (29,4)	12 (35,3)
1%				
Solução glicosilada	8 (24,2)	7 (21,2)	13 (39,4)	5 (15,2)
2,4%				
Solução glicosilada	7 (20,6)	12 (35,3)	10 (29,4)	5 (14,7)
4%				
Solução glicofisiológica (SF0,9% + SG4%) nas mesmas proporções	7 (24,1)	8 (27,6)	6 (20,7)	8 (27,6)
Ringer lactato	0 (0,0)	0 (0,0)	1 (2,9)	33 (97,1)
Albumina	2 (6,9)	8 (27,6)	6 (20,7)	13 (44,8)
Amido	9 (26,5)	13 (38,2)	9 (26,5)	3 ( 8,8)
Gelatina	7 (24,1)	13 (44,9)	6 (20,7)	3 (10,3)
Dextrans	11 (32,4)	15 (44,1)	6 (17,6)	2 (5,9)

**Tabela 4 – Eventos adversos**

Variáveis	Discordo totalmente	Discordo	Não concordo nem discordo	Concordo
	n (%)	n (%)	n (%)	n (%)
<b>Eventos adversos relacionados ao Ringer Lactato</b>				
Edema periférico	0 (0,0)	5 (14,7)	3 (8,8)	26 (76,5)
Edema pulmonar	2 (5,9)	3 (8,8)	6 (17,6)	23 (67,6)
Hipercoagulabilidade	9 (26,5)	14 (41,1)	4 (11,8)	7 (20,6)
<b>Eventos adversos do SF 0,9%</b>				
Acidose hiperclorêmica	0 (0,0)	1 (3,0)	2 (6,1)	30 (90,9)
Estados hiperosmolares	2 (5,9)	11 (32,4)	2 (5,9)	19 (55,8)
Retenção de fluidos	3 (8,8)	8 (23,5)	2 (5,9)	21 (61,8)
<b>As soluções Balanceadas tem menor chance de causar acidose em relação ao Soro Fisiológico 0,9%. Grandes volumes de cristaloides podem causar acidose</b>	0 (0,0)	0 (0,0)	4 (11,8)	30 (88,2)
	0 (0,0)	0 (0,0)	0 (0,0)	34 (100,0)

**Tabela 5 – Eventos adversos**

Variáveis	Discordo	Discordo	Não	Concordo
-----------	----------	----------	-----	----------

	totalmente		concordo nem discordo	
	n (%)	n (%)	n (%)	n (%)
<b>São eventos adversos dos colides sintéticos</b>				
Reação anafilática	1 (2,9)	2 (5,9)	0 (0,0)	31 (91,2)
Coagulopatia	1 (2,9)	1 (2,9)	3 (8,8)	29 (85,4)
Insuficiência renal	0 (0,0)	4 (11,8)	2 (5,9)	28 (82,4)
<b>São eventos adversos da albumina</b>				
Reação anafilática.	3 (9,1)	4 (12,1)	0 (0,0)	26 (78,8)
Coagulopatia	3 (9,4)	10 (31,3)	4 (12,5)	15 (46,8)
Insuficiência renal.	1 (3,1)	9 (28,1)	4 (12,5)	18 (56,3)
<b>São eventos adversos das Soluções Glicosadas</b>				
Hiponatremia	0 (0,0)	1 (2,9)	2 (5,9)	31 (91,2)
Hiperglicemia	0 (0,0)	4 (11,8)	0 (0,0)	30 (88,2)
Dano cerebral	0 (0,0)	4 (11,8)	3 (8,8)	27 (79,4)

**Tabela 6– Volumes**

Variáveis	Discordo totalmente	Discordo	Não concordo nem discordo	Concordo
	n (%)	n (%)	n (%)	n (%)
<b>Na sua rotina, você utiliza</b>				
Estratégia restritiva	2 (5,9)	13 (38,2)	6 (17,7)	13 (38,2)
Estratégia liberal	2 (6,1)	17 (51,5)	8 (24,2)	6 (18,2)
Guiada por metas	0 (0,0)	0 (0,0)	0 (0,0)	34 (100,0)
<b>São eventos adversos da estratégia Restritiva</b>				
Lesão renal aguda	0 (0,0)	0 (0,0)	1 (2,9)	32 (94,1)
<b>São eventos adversos da estratégia Liberal</b>				
Descompensação cardiopulmonar	0 (0,0)	0 (0,0)	0 (0,0)	34 (100,0)
Complicações de cicatrização tecidual	0 (0,0)	2 (5,9)	3 (8,8)	29 (85,3)
<b>Conhece a fórmula de Holliday e Segar (4/2/1) para cálculo do volume de reposição</b>				
Conhece a fórmula de Furman (4mL/kg/ hora de jejum dividido nas 2 primeiras horas) para cálculo do volume de	3 (8,8)	0 (0,0)	6 (17,6)	25 (73,5)
	3 (8,8)	6 (17,6)	5 (14,7)	20 (58,8)

**reposição**

**Conhece a fórmula de Berry (25 mL/kg para menores de 3 anos, 15 mL/Kg para maiores de 3 anos, manutenção 4mL/kg + reposição do porte cirúrgico 2/4/6) para cálculo do volume de reposição**

4 (12,1)      8 (24,2)      7 (21,2)      14 (42,5)

**Métodos descritos você utiliza atualmente**

Holliday e Segar      3 (8,8)      5 (14,7)      5 (14,7)      21 (61,8)

Furman      3 (8,8)      9 (26,5)      13 (38,2)      9 (26,5)

Berry      4 (11,8)      9 (26,5)      12 (35,2)      9 (26,5)

---



# BRAZILIAN JOURNAL OF ANESTHESIOLOGY

Official Publication of the [Brazilian Society of Anesthesiology](#)

Incorporating *Revista Brasileira de Anestesiologia* (ISSN 0034-7094) as of 2021.

## AUTHOR INFORMATION PACK

### TABLE OF CONTENTS

- **Description** p.1
- **Abstracting and Indexing** p.1
- **Editorial Board** p.1
- **Guide for Authors** p.4



### DESCRIPTION

The *Brazilian Journal of Anesthesiology* (BJAN) is the official journal of the Brazilian Anesthesiology Society.

The BJAN publishes original work in all areas of anesthesia, surgery, critical care, perioperative medicine, and pain medicine, including basic, translational, and clinical research, as well as education and technological innovation.

The journal welcomes manuscripts in the following formats: Original investigation Review Case report Letter to the editor Short communication Clinical image

Since 2021, *Revista Brasileira de Anestesiologia* (0034-7094) has merged into the *Brazilian Journal of Anesthesiology* (0104-0014), adopting English as its main publishing language.

### ABSTRACTING AND INDEXING

Directory of Open Access Journals (DOAJ)  
PubMed/Medline

### EDITORIAL BOARD

#### *Editor-in-Chief*

**Maria José Carvalho Carmona**, Faculdade de Medicina. Universidade de São Paulo, São Paulo, SP, Brazil

#### *Co-editor*

**André Prato Schmidt**, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

#### *Associate Editors*

**Rodrigo Leal Alves**, Hospital São Rafael, Salvador, BA, Brazil

**Vinicius Caldeira Quintão**, Hospital das Clínicas. Universidade de São Paulo, São Paulo, SP, Brazil

**Florentino Fernandes Mendes**, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil

**Leonardo Henrique Cunha Ferraro**, Universidade Federal de São Paulo, São Paulo, Brazil

**Marcello Fonseca Salgado-Filho**, Universidade Federal Fluminense, Niterói, RJ, Brazil

**Luis Vicente Garcia**, Universidade de São Paulo Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil



**Vanessa Henriques Carvalho**, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil  
**Gabriel Magalhães Nunes Guimarães**, Universidade de Brasília, Brasília, DF, Brazil  
**Cláudia Marquez Simões**, Hospital Sírio Libanês, São Paulo, SP, Brazil  
**Ana Maria Menezes Caetano**, Universidade Federal de Pernambuco, Recife, PE, Brazil  
**Guilherme Antonio Moreira Barros Lima**, Faculdade de Medicina de Botucatu. Universidade Estadual Paulista, Botucatu, SP, Brazil  
**Paulo do Nascimento Junior**, Universidade Estadual Paulista Julio de Mesquita Filho Faculdade de Medicina Campus de Botucatu, Botucatu, Brazil  
**Norma Sueli Pinheiro Módolo**, Universidade Estadual Paulista Julio de Mesquita Filho Faculdade de Medicina Campus de Botucatu, Botucatu, Brazil  
**Luiz Marcelo Sá Malbouisson**, Universidade de Sao Paulo Faculdade de Medicina Hospital das Clinicas, SAO PAULO, Brazil  
**Luciana Paula Cadore Stefani**, Universidade Federal do Rio Grande do Sul Departamento de Astronomia, Porto Alegre, Brazil  
**Liana Maria Torres de Araújo Azi**, Federal University of Bahia, Faculty of Medicine, Department of Pediatrics, Salvador, Brazil

#### **Editorial Board**

**Fernando Abelha**, Hospital de São João, Porto, Portugal  
**Marcelo Luis Abramides Torres**, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil  
**Hazem Adel Ashmawi**, Universidade de São Paulo, São Paulo, SP, Brazil  
**Antônio Carlos Aguiar Brandão**, Universidade do Vale do Sapucaí, Pouso Alegre, MG, Brazil  
**Paulo Alípio**, Universidade Federal Fluminense, Niterói, Brazil  
**Adrian Alvarez**, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina  
**Pedro Amorim**, Centro Hospitalar e Universitário do Porto, Porto, Portugal  
**Alexandra Rezende Assad**, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil  
**Federico Bilotta**, Sapienza Università Di Roma, Rome, Italy  
**Bernd w. Böttiger**, Universitat zu Koln, Cologne, Germany  
**Pedro Francisco Brandão**, Universidade Federal do Espírito Santo, Vitória, Espírito Santo, Brazil  
**Leandro Gobbo Braz**, Universidade Estadual Paulista Julio de Mesquita Filho Faculdade de Medicina Campus de Botucatu, Botucatu, Brazil  
**Emery Brown**, Massachusetts Institute of Technology, Cambridge, MA, United States of America  
**Durval Campos Kraychete**, Universidade Federal da Bahia, Salvador, BA, Brazil  
**Thaís Cançado**, Serviço de Anestesiologia de Campo Grande, Campo Grande, Mato Grosso do Sul, Brazil  
**Ricardo Vieira Carlos**, Universidade de Sao Paulo Faculdade de Medicina Hospital das Clinicas, SAO PAULO, Brazil  
**Wolnei Caumo**, Universidade Federal do Rio Grande do Sul Departamento de Astronomia, Porto Alegre, RS, Brazil  
**Raffael Pereira Cezar Zamper**, London Health Sciences Centre, London, Ontario, Canada  
**Felipe Chiodini**, Universidade de Sao Paulo Faculdade de Medicina, Sao Paulo, Brazil  
**Domingos Cicarelli**, Hospital das Clínicas. Universidade de São Paulo, São Paulo, SP, Brazil  
**Mário José da Conceição**, Fundação Universidade Regional de Blumenau, Blumenau, SC, Brazil  
**Nádia Maria da Conceição Duarte**, Universidade Federal de Pernambuco, Recife, PE, Brazil  
**Carlos Manuel Correia Rodrigues de Almeida**, Hospital CUF Viseu, Viseu, Portugal  
**Marcos Antonio Costa de Albuquerque**, Universidade Federal de Sergipe, São Cristóvão, SE, Brazil  
**Deborah Culley**, Harvard University, Cambridge, MA, United States of America  
**Nicola Disma**, Istituto Giannina Gaslini, Genova, Italy  
**Gastão Durval Neto**, Universidade Federal de Pelotas, Pelotas, RS, Brazil  
**Matheus Fachini Vane**, Universidade de Sao Paulo Faculdade de Medicina Hospital das Clinicas, São Paulo, SP, Brazil  
**David Ferez**, Universidade Federal de São Paulo, São Paulo, SP, Brazil  
**Claudia Regina Fernandes**, Universidade Federal do Ceara, Fortaleza, Ceará, Brazil  
**Fátima Carneiro Fernandes**, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil  
**Carolina Baeta Neves Duarte Ferreira**, Hospital Moriah, São Paulo, SP, Brazil  
**Sara Lucia Ferreira Cavalcante**, Hospital Geral do Inamps de Fortaleza, Fortaleza, CE, Brazil  
**Neuber Martins Fonseca**, Universidade Federal de Uberlândia, Uberlândia, MG, Brazil  
**Carlos Galhardo Júnior**, Instituto de Cardiologia, Rio de Janeiro, RJ, Brazil  
**Marcelo Gama de Abreu**, University Hospital Carl Gustav Carus, Dresden, Germany  
**Luciano Gattinoni**, Georg-August-Universität Göttingen, Göttingen, Germany  
**Adrian Gelb**, University of California, San Francisco, CA, United States of America  
**Célio Gomes de Amorim**, Universidade Federal de Uberlândia, Uberlândia, MG, Brazil  
**Ricardo Antônio Guimarães Barbosa**, Universidade de Sao Paulo Faculdade de Medicina Hospital das Clinicas, São Paulo, SP, Brazil  
**Eduardo Giroud Joaquim**, Universidade Federal de Sao Paulo, São Paulo, Brazil  
**João Paulo Jordão Pontes**, Universidade Federal de Uberlandia, Uberlandia, Brazil  
**Rajinder K. Mirakhur**, Belfast Health and Social Care Trust, Belfast, Northern Ireland  
**Augusto A. Key Karazawa Takaschima**, Sianest, Florianópolis, SC, Brazil

**Giovanni Landoni**, Vita-Salute San Raffaele University, Milan, Italy  
**Judymara Lauzi Gozzani**, Universidade Federal de São Paulo, São Paulo, SP, Brazil  
**Ismar Lima Cavalcanti**, Hospital Geral de Nova Iguaçu, Nova Iguaçu, RJ, Brazil  
**Mariana Fontes Lima Neville**, Universidade Federal de Sao Paulo, São Paulo, Brazil  
**Rodrigo Lima**, Queen's University, Kingston, Ontario, Canada  
**Eric Benedet Lineburger**, Hospital São José, Criciúma, Santa Catarina, Brazil  
**Luiz Marciano Cangiani**, Centro Medico de Campinas, Campinas, Brazil  
**Clarita Bandeira Margarido**, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada  
**Clyde Matava**, The Hospital for Sick Children, Toronto, Ontario, Canada  
**Márcio Matsumoto**, Hospital Sirio-Libanês, Sao Paulo, Brazil  
**Frederic Michard**, MiCo Consulting and Research, Denens, Switzerland  
**Ronald Miller**, University of California, San Francisco, CA, United States of America  
**Lais Helena Navarro e Lima**, Queen's University, Kingston, Ontario, Canada  
**Priscilla Ferreira Neto**, Universidade de Sao Paulo Faculdade de Medicina Hospital das Clinicas Instituto da Criança, SAO PAULO, Brazil  
**Gildásio de Oliveira Júnior**, Brown University Warren Alpert Medical School, Providence, Rhode Island, United States of America  
**Fábio Papa**, University of Toronto, Toronto, Ontario, Canada  
**Waynice Paula-Garcia**, University of Sao Paulo, São Paulo, Brazil  
**Paolo Pelosi**, Università Degli Studi Di Genova, Genova, Italy  
**Fabiana Aparecida Penachi Bosco Ferreira**, Universidade Federal de Goiás, Goiânia, GO, Brazil  
**Philip Peng**, University of Toronto, Toronto, Ontario, Canada  
**Oscar Cesar Pires**, Universidade de Taubaté, Taubaté, SP, Brazil  
**Luiz Fernando dos Reis Falcão**, Universidade Federal de São Paulo, São Paulo, SP, Brazil  
**Rogean Rodrigues Nunes**, Hospital São Lucas, Fortaleza, CE, Brazil  
**Jean Jacques Rouby**, Pierre and Marie Curie University, Paris, France  
**Kurt Ruetzler**, Cleveland Clinic Foundation, Cleveland, OH, United States of America  
**Luis Antônio dos Santos Diego**, Universidade Federal Fluminense, Niterói, RJ, Brazil  
**João Batista Santos Garcia**, Universidade Federal do Maranhão, São Luís, MA, Brazil  
**Mônica Maria Siaulys**, Hospital e Maternidade Santa Joana, São Paulo, SP, Brazil  
**João Manoel da Silva Júnior**, Hospital do Servidor Público, São Paulo, SP, Brazil  
**Leopoldo Muniz da Silva**, Universidade Estadual Paulista Julio de Mesquita Filho Faculdade de Medicina Campus de Botucatu, Botucatu, Brazil  
**Ligia Andrade da Silva Telles Mathias**, Irmandade da Santa Casa de Misericórdia de São Paulo, , São Paulo, SP, Brazil  
**Massimiliano Sorbello**, Policlinico Vittorio Emanuele San Marco University Hospital, Department of Anesthesia and Intensive Care, Catania, Italy  
**Angela Maria de Sousa**, Universidade de Sao Paulo Faculdade de Medicina Hospital das Clinicas, SAO PAULO, Brazil  
**Cátia Sousa Govêia**, Universidade de Brasília, Brasília, DF, Brazil  
**Edmundo Pereira de Souza Neto**, Centre Hospitalier de Montauban, Montauban, France  
**Eliane Cristina de Souza Soares**, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil  
**Bobbie Jean Sweitzer**, Northwestern Medicine, Chicago, IL, United States of America  
**Pedro Paulo Tanaka**, Stanford University School of Medicine, Stanford, CA, United States of America  
**Maria Ângela Tardelli**, Universidade Federal de São Paulo, São Paulo, SP, Brazil  
**Jean-Louis Teboul**, Paris-Saclay University Hospital Bicetre Medical Intensive Care Unit, Paris, France  
**Marcos Francisco Vidal Melo**, Harvard University, Cambridge, MA, United States of America  
**Jean Louis Vincent**, Université Libre De Bruxelles, Brussels, Belgium  
**Laszlo Vutskits**, Université de Genève, Geneva, Switzerland

## GUIDE FOR AUTHORS

---

### *Instructions to Authors: before submitting*

Before submitting a manuscript, authors should read the present Instructions to authors carefully and adhere to them. Problems with submissions should be reported to the Editorial Office. Decisions on submissions are final and will take place in approximately 8 - 12 weeks.

### INTRODUCTION

The Brazilian Journal of Anesthesiology (**BJAN**) is the official journal of the Brazilian Society of Anesthesiology (Sociedade Brasileira de Anestesiologia, SBA), which supports the journal completely - the cost of publishing is on behalf of the **SBA, with no charges to authors.**

The BJAN publishes original work in all areas of anesthesia, surgery, critical care, perioperative medicine, and pain medicine, including basic, translational, and clinical research, as well as education and technological innovation. Special articles such as guidelines and historical manuscripts are published upon invitation only, and authors should seek subject approval by the Editorial Office before submission.

The BJAN accepts only original articles that are not under consideration by any other journal and that have not been published before, except as academic theses, preprints, or abstracts presented at conferences or meetings, which must be specified in the cover letter. A cloud-based intuitive platform is used to compare manuscripts submitted to previous publications, and submissions must not contain any instances of plagiarism. Authors must obtain and send the Editorial Office all required permissions for any overlapping material and properly identify them in the manuscript to avoid plagiarism.

All articles submitted for publication are assessed by two or more members of the Editorial Board or external peer reviewers, assigned at the discretion of the Editor-in-chief or the Associate Editors.

Since 2021, the *Revista Brasileira de Anestesiologia* (0034-7094) was merged into the *Brazilian Journal of Anesthesiology* (0104-0014), adopting English as its main publishing language.

ISSNs:

2352-2291 Brazilian Journal of Anesthesiology (Online)

0104-0014 Brazilian Journal of Anesthesiology (Print)

The abbreviation of its title is **Braz J Anesthesiol**, which should be used in bibliographies, footnotes, bibliographic references, and legends.

All editorial communications should be addressed to the Editor-in-Chief (editor.bjan@sbahq.org).

### *Types of article*

#### **Original investigation**

Primary clinical, observational, or experimental research information. Each kind of study will contain different elements. A copy or link of the ethical approval of the study, as well as its registry, must be submitted along with the manuscript. For a list of registry platforms for clinical trials, assess the International Clinical Trials Registry Platform (**ICTRP**) . Brazilian researchers are advised to register at **ReBEC**.

*Maximum of 3,000 words, 30 references, 6 tables or figures. Must present a structured abstract up to 250 words.*

#### **Reviews**

##### *Systematic review*

Authors should register the review protocol in **PROSPERO** (International Prospective Register of Systematic Reviews) and must state the review protocol in the Methods section and indicate where it can be accessed. Summarize sections by pulling together the implications of main findings, avoiding just the repetition of the results of previously published studies, searching for an expanded evidence-based conclusion. Incorporating the results of a new study with previous relevant studies in a meta-analysis is encouraged.

*Maximum of 4,000 words, 100 references, 6 tables or figures. Must present an structured abstract up to 250 words.*

#### *Narrative review*

As a rule, narrative reviews are written by invitation from the Editor-in-chief. If you were not invited, before submitting a review you should contact the Editor-in-chief, who will evaluate the appropriateness of the proposal to the Journal, avoiding publishing duplications. A systematic review, as well as scoping review, rapid review, state-of-art review, and overview of reviews can be considered for publication.

*Maximum of 4,000 words, 100 references, 6 tables or figures. Must present an unstructured abstract up to 250 words.*

#### *Scoping review*

Scoping reviews may be an exercise to examine emerging evidence and evaluate specific questions before conducting a systematic review, which can later be developed based on it. We suggest registration/publication of scoping review protocols. Examples of databases where scoping reviews may be registered are Open Science Framework ([OSF](#)) and [Figshare](#).

*Maximum of 4,000 words, 100 references, 6 tables or figures. Must present an unstructured abstract up to 250 words.*

#### *Rapid review*

Rapid reviews aim to evaluate what is known about specific topics, guiding health policies. The methods are the same as those for systematic reviews, focusing on important points with more liberal protocols of bibliographic research, restricted analysis of gray literature, and a more simplified evaluation of the quality of publications.

*Maximum of 4,000 words, 100 references, 6 tables or figures. Must present an unstructured abstract up to 250 words.*

#### *State-of-art review*

A narrative review about most current matters. It may offer different perspectives on the topic or denote areas for future research. This is an important review for the new reader in an area, or whoever is trying to identify potential opportunities for contemporary research.

*Maximum of 4,000 words, 100 references, 6 tables or figures. Must present an unstructured abstract up to 250 words.*

#### *Overview of reviews*

This is a general review of reviews which may or may not include systematic reviews. It provides a broad and often comprehensive summary of an area or topic and it is important for the reader who addresses a subject for the first time.

*Maximum of 4,000 words, 100 references, 6 tables or figures. Must present an unstructured abstract up to 250 words.*

### **Case report**

BJAN only accepts for publication clinical information or case reports that describe innovations, novelties or new clinical approaches for already established clinical problems. They must contain impactful information, other than just the introduction of techniques, methods or medical devices. A copy of the Institutional Research Board approval must be submitted along with case reports. If any kind of patient image is used, it must be unidentified and anonymized and a specific signed authorization for publication should be obtained from the patient, legal guardians or family and submitted along with the report.

*Maximum of 1,500 words, 5 references, 2 tables or figures. Must present an unstructured abstract up to 100 words.*

### **Letter to the editor**

Letters to the editor should include constructive, objective and educational comments on already published **BJAN** papers or be freestanding. Reporting research findings or cases reports as letters to the editor **is not advised**. Freestanding letters to the editor may discuss matters of interest to readers without linkage to papers already published in **BJAN**. Letters will be published at the sole discretion of the Editor-in-chief.

*Maximum of 1,000 words, 5 references, 1 table or figure. No abstract is needed.*

**Short communication** A Short communication is a simple research study with an interesting result. It is unstructured (no subheadings) and has no abstract. It should include basic brief features of background, methods, results, and discussion. If it involves human or animals, ethics approval is required.

*Maximum of 1,500 words, 10 references, 2 tables or figures. No abstract is needed*

### **Clinical image**

Images with clinical relevance for the area. *Maximum of 200 words, 3 references, 3 tables or figures. No abstract is needed*

### **Editorial**

Editorials must be submitted only with the editor-in-chief previous approval.

*Maximum of 2000 words, 15 references, 2 tables or figures. No abstract is needed*

### **Language**

English (US) is the official language of **BJAN**, which receives submissions in English and Portuguese. After acceptance, articles will be indexed only in English and a version in Portuguese will be available at [BJAN's website: bjan-sba.org](http://bjan-sba.org).

If required, before acceptance of the article, the author must send it to a certified English review, such as American Journal Experts ([AJE](#)), [Enago](#) and Proof-Reading-Service ([PRS](#)).

### **Submission**

Submissions must have the following elements: Cover Letter, Title page, Abstract with Keywords, Manuscript without author's details (blind), Tables + Figures, BJAN's [Copyright](#) and [Agreement](#) forms. Before submitting, please check the [Submission Checklist](#).

### **Cover letter**

Focus on the novelty and value of the author's work, the relation to the scope of BJAN, and stating why the editor should consider the article for publication. Specify that the article was not previously published (or if it was published as preprint or academic work). The cover letter will not be part of the final published manuscript.

Also, please indicate word count, including tables, and figures of the manuscript submitted.

#### *Preprints*

At the discretion of the Editorial board, preprints can be shared any time and will not count as prior publication but must be cited in the submission.

#### *Submission declaration and verification*

Submission of an article implies that the work described has not been published previously, except in the form of an abstract, as part of a published lecture or academic thesis, or as an electronic preprint. It also means that the manuscript is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out.

If accepted, it must not be published elsewhere in the same form, in any language, including electronically without the written consent of the copyright-holder. Your article will be checked by the originality detection service [Ithenticate](#). See [Multiple, redundant or concurrent publication](#).

### **Title page**

The title page should include: The actual *title* and the *running title*. *Authorship*, with the names, affiliations, ORCID and contributions of all authors, clearly indicating the corresponding author (who will be responsible for all the communications with the journal). If the authors still do not have an [ORCID](#), it can be registered at <https://orcid.org/Copy> of or link to the *Institutional Research Board approval* of the submission and the link to the *study registry*.

### **Abstract**

An abstract, with the headings background, methods, results and conclusion, should provide the context for the research and state its purpose, basic procedures (selection of study subjects or laboratory animals, observational and analytical methods), main findings (giving specific size effects and their statistical significance, if possible), and main conclusions. It should emphasize new and important aspects of the study or observations.

*Keywords*

Provide a maximum of six keywords in alphabetical order and separated by commas to represent the content of the article. Descriptors or keywords should be based on [DECS](#) or [MeSH](#).

## **Manuscript**

Please send it as an editable word file (preferably Word).

### *Title*

The title must be concise and informative, as it is often used in information-retrieval systems. Avoid abbreviations and formulae if you can, as well as commercial and copyrighted names. Write the title in the simplest way possible, thinking, how would I search for this subject in a database or on the internet. It must include the study design.

Titles must be written in the same language as the manuscript, with only the first letter in uppercase.

### *Abstract + Keywords*

Must be included as specified above.

### *Introduction*

Provide adequate background, avoiding a detailed literature survey or a summary of the results. Specify the hypothesis which justifies the study. State the objectives of the trial.

### *Methods*

Provide sufficient detail to allow the work to be reproduced. Methods already published in detail elsewhere should be indicated by a reference citation, describing the methods concisely, as the reader might not have access to the original protocol publication, especially if it is not open access. All modifications from the study protocol should be described.

### *Results*

Results should be clear, concise, and contextualized. Avoid the repetition of data in the text and in the tables or figures.

### *Discussion*

Explore the significance of the results of the study, without repeating them. Confront your data with previous findings, avoiding extensive citations and discussion of already published literature. Discuss the limitations of the study and critically justify them. Emphasize the importance of the study for the current state-of-art as well as the future perspectives related to the study.

### *Conclusions*

The main conclusions of the study should be presented in a short Conclusions section.

### *Acknowledgements*

Collate acknowledgements in a separate section at the end of the article, before the references. List those individuals who provided help during the research (e.g., providing help with language, writing assistance, proofreading the article, etc.).

### *References*

All references must be presented according to the [Vancouver Style](#), and journal names should be abbreviated according to the [List of Title Word Abbreviations](#).

To allow for the creation of links to abstracting and indexing services, please ensure that the data provided in the references are correct. A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article.

All references must be numbered (superscript) in the same sequence as they are cited in the text. Please check the maximum according to the type of manuscript.

### *Tables and figures*

All tables and figures must be cited in the text in sequence and be placed only at the end of the file, not in the middle of the text. Please check the maximum of Tables + Figures according to the type of article. They should preferably be sent in an editable file to be translated.

## **Other topics**

### *Funding sources*

Identify who provided financial support and briefly describe the role of the sponsor(s). If the funding source had no such involvement, it should be stated as well. List funding sources in a standard format to facilitate compliance to funders requirements. (i.e., This work was supported by the CNPq [grant number xxxx] and FAPESP [grant number xxxx]). It is not necessary to include detailed descriptions on the program or type of grants and awards.

When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided it.

If no funding has been provided for the research, please include the following sentence: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors?.

### *Abbreviations*

Define abbreviations that are not standard in this field in the first presentation in the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there. Ensure consistency of abbreviations throughout the article.

### *Units*

Follow internationally accepted rules and conventions. Use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

### *Footnotes*

Footnotes should be used sparingly. Use of references is preferable.

## **BEFORE YOU BEGIN**

### ***Studies in humans and animals***

#### **Studies in animals**

All animal experiments should comply with the [ARRIVE](#) guidelines and be carried out in accordance with local country regulations. It is fundamental to clearly indicate in the manuscript that such guidelines have been followed and upload the guidelines? checklist.

It must indicate: the sex of animals and, when appropriate, the influence (or association) of sex on the results of the study; the genotype, strain, source, and number of backcrosses and age of the animals studied.

#### **Studies in humans**

If the article involves human subjects, the author should ensure that the research described has been carried out in accordance with The Code of Ethics of the World Medical Association ([Declaration of Helsinki](#)) for experiments involving humans. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. Privacy rights must always be observed.

The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals <http://www.icmje.org/icmje-recommendations.pdf> and aim for the inclusion of representative human populations (sex, age, and ethnicity) as per those recommendations. The manuscript must contain data on the age (mean with range), height (m), weight (kg), sex (male/female, with numbers and percentages), criteria for selection, health conditions, among others that are significant to study results. It is better to present complex information in a table to facilitate understanding of the data. *Informed consent and patient details*: require Institutional Ethical Committee or Internal Review Board (IRB) approval and informed consent documented in the paper. Appropriate consents, permissions and releases must be obtained when an author wishes to include case details, other personal information, or images of patients or any other individuals. Please indicate it was obtained, but there is no need to upload them, unless specifically requested by the journal. *Images*: must be deidentified and anonymized, and a specific signed authorization for publication should be obtained from the patient, legal guardians or family and submitted along with the manuscript or case report. If there is no written permission, personal details of any patient included in any part of the article and in any supplementary materials (including illustrations and videos) must be removed before submission.

### ***Declaration of interest***

All authors must disclose any financial and personal relationships with other individuals or organizations that could inappropriately influence (bias) their work ([Conflicts of Interest Statement](#)). If there are no conflicts of interest, please state: "Conflicts of interest: none".

### ***Use of inclusive language***

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Authors should make no assumptions about the beliefs or commitments of any reader. The text should present nothing that might imply that one individual is superior to another on the grounds of race, sex, culture, or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias.

### ***Authorship***

BJAN adopts [ICMJE](#) criteria for authorship. Each author is required to declare his or her individual contribution to the article. All authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure statement.

All authors should have made substantial contributions to the following: conception and design of the study, or acquisition of data, or analysis and interpretation of data; drafting the article or revising it critically for important intellectual content; final approval of the version to be submitted.

#### *Changes to authorship*

Any addition, deletion, or rearrangement of author names in the authorship list should be made before the manuscript has been accepted. To request such a change, the corresponding author must specify the reason for the change in the author list and send written confirmation from all authors that they agree with the addition, removal, or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

While the Editor-in-chief considers the request, publication of the manuscript will be suspended. If the manuscript has already been published, any requests approved by the Editor-in-chief will result in a corrigendum.

#### *Copyright and agreement*

At the moment of submission, authors must upload, along with the article, a digital signed copy of two documents:

**Agreement for Authors:** by signing this Agreement, the Author(s), ensures being the copyright owner and licenses to BJAN the exclusive rights of the manuscript submitted. If accepted, Authors assign to BJAN the right to publish and distribute the manuscript in part or in its entirety.

**Private Copyright Assignment Term:** by signing and presenting this term, the author(s) assigns and transfers all ownership copyrights regarding the work unto the Brazilian Society of Anesthesiology (SBA), assignee. Authors can sign altogether or several individual copies.

Along with the submission process, authors will be asked to complete the Journal Publishing Agreement <http://www.elsevier.com/about/policies/copyright>. This document includes any tables, illustrations or other material submitted for publication as part of the manuscript, in all forms and media (whether now known or later developed) throughout the world, in all languages, for the full term of copyright, effective when the Article is accepted for publication. An e-mail will be sent to the corresponding author confirming receipt of the submitted manuscript with a "Journal Publishing Agreement" form or a link to the online version of this agreement.

#### **Plagiarism and Editorial misconduct**

The **BJAN** accepts **only original** articles that **are not** under consideration by any other journal and that have not been published before, except as academic theses, preprints, or abstracts presented at conferences or meetings. A cloud-based intuitive platform is used to compare submitted manuscripts to previous publications, and submissions must not contain any instances of plagiarism. Authors must obtain and send the Editorial Office all required permissions for any overlapping material and properly identify them in the manuscript to avoid plagiarism.

For more information about Ethics in Publishing in Portuguese, read [Good Practices Guide for Ethics in Scientific Publishing](#) from Scielo.

#### **Reporting guidelines**

BJAN mandates the use of an appropriate reporting guideline when writing any health research manuscript. Guidance on each type of study and how to choose the correct reporting guideline can be found on the [EQUATOR](#) website, and authors must submit completed checklists for the relevant reporting guidelines (and flow diagram, if applicable) they followed along with the manuscript. Using a checklist helps to ensure that the reporting guideline was used correctly and helps the editors and reviewers to complete the same check. If the checklist indicates an item that you have not addressed in your manuscript, explain in the manuscript text why this information is not relevant to your study or add the relevant information.

Read the article [Reporting guidelines: tools to increase the completeness and transparency of your anesthesiology research paper](#) for more on this topic.

#### **What reporting guideline to use**

*Research on an intervention, treatment, exposure, or protective factor on human subjects*

- Use the [ACRE guideline](#) to report cases in anesthesia and perioperative medicine.
- Use the [CARE guideline](#) for reporting one case study or a series of case studies.
- Use the [CONSORT guideline](#) or one of its extensions: if you selected your participants before they received the intervention/exposure/etc. under study, AND you controlled which intervention/exposure/etc. they each received, AND you used a random allocation method to decide which intervention/exposure/etc. they each received.



- Use the [STROBE guideline](#) or one of its extensions: If you selected your participants after they received the intervention/exposure/etc. under study, OR you selected your participants before they received the intervention/exposure/etc. under study AND you did not control which intervention/exposure/etc. they received (they decided/their doctor decided/life just happened).
- Use the [TREND guideline](#) if you selected your participants before they received the intervention/exposure/etc. under study, AND if CARE, CONSORT, and STROBE are not applicable to your research AND you used a non-random way to decide which intervention/exposure/etc. your participants received, such as which hospital they went to or what their clinical symptoms were.
- Use the [SPIRIT guideline](#) for the protocol of a clinical trial if you are reporting a protocol.

#### *Literature review*

- Use the [ENTREQ guideline](#) for a review of studies that use descriptive data, such as unstructured interviews (qualitative data).
- Use the [MOOSE guideline](#) for a review of observational studies.
- Use the [PRISMA guideline](#) for any other kind of systematic review or meta-analysis.
- Use the [PRISMA-P](#) guideline for the protocol of a systematic review.
- Use the [PRISMA ScR](#) guideline for scoping reviews.

#### *Animal research*

- Use the [ARRIVE guideline](#) for research on animals in a lab.
- Use the [REFLECT guideline](#) for research on livestock.

#### *Descriptive data (either alone or alongside quantitative data)*

- Use the [COREQ guideline](#) for reporting unstructured interviews and focus groups.
- Use the [CARE guideline](#) for reporting one case study or a series of case studies.
- Use the [SRQR guideline](#) for any other descriptive data (qualitative research).

#### *Research into diagnosis*

- Use the [STARD guideline](#) if you compared the accuracy of a diagnostic test with an established reference standard test.
- Use the [REMARK guideline](#) if you evaluated the prognostic value of a biomarker.
- Use the [TRIPOD guideline](#) if you developed, validated, or updated a prognostic or diagnostic prediction modelling tool.

#### *Research on an intervention or treatment on human subjects*

- Use the [TIDieR guideline](#) to fully describe your intervention.
- Use the [CHEERS guideline](#) for an economic

## **PREPARATION**

### **Use of word processing software**

It is important that the manuscript file be saved in the native format of the Word processor used. It is important that the manuscript file be saved in the native format of the Word processor used. The text should be presented:

- In Arial or Times New Roman fonts, size 12, 1,5 line spacing
- In single single-column format and layout as simple as possible.
- Do not use the Word processor's options to justify text or to hyphenate words.
- When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns.
- All figures and tables must be presented at the end of the manuscript, after the references, and cited in the text.
- To avoid unnecessary errors, you are strongly advised to use the "spell-check" and "grammar-check" functions of your Word processor (US English or Brazilian Portuguese).
- Use TAB instead of SPACE for tables and paragraphs.

If **English is not your native language** and the Editor-in-chief asks you to revise orthography of your text, please submit your article for grammar correction by a qualified company, such as **American Journal Experts (AJE)**, **Enago**, and **Proof-Reading-Service (PRS)**, before acceptance for publication. You can also do that before submitting your text for the first time if it makes you feel more comfortable, even if English is your native language.

### **Artwork**

#### **Image editing**

The authors sometimes need to edit images for clarity, although editing for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. No specific feature within an image may be enhanced, obscured, moved, removed, or introduced; Adjustments of brightness, contrast, or color balance are acceptable if, and as long as, they do not obscure or eliminate any

information present in the original; Nonlinear adjustments must be disclosed in the figure legend; The resolution of the material must be 300+ dpi; Make sure you use uniform lettering and sizing in your original artwork; Number the illustrations according to their sequence in the text; Use a logical naming convention for your artwork files.

### *Formats*

Regardless of the application used, when your electronic artwork is finalized, please "save as" or convert the images to one of the following formats: EPS (or PDF): Vector drawings. Embed the font or save the text as "graphics" TIFF (or JPG): Color or grayscale photographs. For halftones, use a minimum of 300 dpi; TIFF (or JPG): Bitmapped line drawings, use a minimum of 1000 dpi; TIFF (or JPG): Combinations bitmapped line/halftone (color or grayscale), a minimum of 500 dpi is required.

*Do not* Supply files that are optimized for screen use, as the resolution is too low; Supply files that are too low in resolution; Submit graphics that are disproportionately large for the content.

### **Figure captions**

Ensure that each illustration has a caption, which should comprise a brief title and a description of the illustration, explaining all symbols and abbreviations used. Supply captions separately, not attached to figures, and keep text in the illustrations themselves to a minimum.

### **Tables**

Please submit tables as editable text, not as images.

They must be placed after the references or on separate pages. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.

### **Video data**

Video material and animation sequences are accepted to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article.

This can be done in the same way as a figure or table, by referring to the video or animation content in the body text. All submitted files should be properly labelled so that they directly relate to the video file's content.

To ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a preferred maximum size of 150 MB. These files will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect.

Please supply stills, choosing any frame from the video or animation or making a separate image, to be used instead of standard icons, personalizing the link to your video data.

### **Supplementary material**

Supplementary material can support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Note that such items are published online exactly as they are submitted; there is no typesetting involved. Submit the material with the article and supply a concise and descriptive caption for each file. If you wish to make any changes to supplementary data during any stage of the process, then please make sure to provide an updated file, and do not annotate any corrections on a previous version. Please also make sure to switch off the "Track Changes" option in any Microsoft Office file, as these will appear in the published supplementary file.

### **Research data**

BJAN encourages you to share data that supports your research publication in an appropriate data repository and enables you to interlink the data with your published articles. If you are sharing data, you are encouraged to cite it in your manuscript and reference list.

### **Data linking**

If you have made your research data available in a data repository, you can link your article directly to the dataset. BJAN collaborates with repositories to link articles on ScienceDirect and others, providing readers access to underlying data that give them a better understanding of the research described.

## **Data statement**

To foster transparency, we encourage you to state the availability of the data in your submission. If your data is unavailable for access or unsuitable to post, this gives you the opportunity to indicate why. If you submit this form with your manuscript as a supplementary file, the statement will appear next to your published article on ScienceDirect.

## **Article structure**

### **Submission checklist**

You can use this list to carry out a final check of your submission before sending it to the journal for review. Ensure that the following items are present at submission:

- Cover letter
- Title page
- Designation of the corresponding author with contact details: e-mail address and ORCID
- Data from all the authors including ORCID
- Copy of or link to the Institutional Research Board approval of the submission, if applicable
- The link to the study registry, if applicable
- Upload of all specific files for the study design: abstract including keywords, manuscript with references; all figures (including relevant captions); all tables (including titles, description, footnotes) ? ensure all figure and table citations in the text match the files provided; supplemental files (where applicable)
- Manuscript has been "spell checked" and "grammar checked"
- All references mentioned in the Reference List are cited in the text, and vice versa
- Completed reporting guideline checklist
- Link to the data repository, if applicable
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- Relevant declarations of interest have been made.

## **Double-blind review**

BJAN operates a double-blind review process, thus the authors must remove from the text all data that can identify them (names, affiliations, etc.) or the institution. Reviewers will not know who is responsible for the work when they are reviewing, and the authors will not know who has reviewed their manuscript at any stage of the publication process as well.

All peer reviewers will be initially assessed by the Editor-in-chief for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor-in-chief is responsible for the final decision regarding acceptance or rejection of articles, which is final.

## **AFTER ACCEPTANCE**

### **Proofs**

One set of page proofs, or a link for access, will be sent by e-mail to the corresponding author so that authors can approve them.

Please use this proof only for checking typesetting, editing, completeness and correctness of the text, tables, and figures. Significant changes to the article accepted for publication will only be considered at this stage with the permission from the editor.

We will do everything possible to get your article published quickly and accurately. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as the inclusion of any subsequent corrections cannot be guaranteed. Proofreading is your responsibility.

[Track your submitted article.](#)

[Track your accepted article.](#)

### **Open Access**

#### **Access rights**

All articles published as open access will be immediately and permanently free for everyone to read, download, copy and distribute.

#### **User rights**

Permitted reuse is defined by the following user license(s):

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND): allows users to copy and distribute the Article, provided this is not done for commercial purposes and does not permit further distribution of the Article if it is changed or edited in any way, and provided the user gives appropriate

credit (with a link to the formal publication through the relevant DOI), provides a link to the license, and that the licensor is not represented as endorsing the use made of the work. The full details of the license are available at <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

#### Author rights

For open access publishing, this journal uses a copyright transfer agreement. Authors will transfer copyright to the Brazilian Society of Anesthesiology (SBA) but will have the right to share their article in the same ways permitted to third parties under the relevant user license, as well as certain scholarly usage rights.

As an author, you (or your employer or institution) have certain [rights to reuse your work](#).

#### **Responsible sharing**

Find out how you can [share your research](#) article published in this journal.

#### **Submit your article**

##### LINKS:

Submission System: <https://www.editorialmanager.com/bjan/default.aspx>

© Copyright 2018 Elsevier | <https://www.elsevier.com>